Your browser doesn't support javascript.
loading
Early versus late response to PD-1-based immunotherapy in metastatic melanoma.
Lodde, Georg C; Zhao, Fang; Herbst, Rudolf; Terheyden, Patrick; Utikal, Jochen; Pföhler, Claudia; Ulrich, Jens; Kreuter, Alexander; Mohr, Peter; Gutzmer, Ralf; Meier, Friedegund; Dippel, Edgar; Weichenthal, Michael; Jansen, Philipp; Kowall, Bernd; Galetzka, Wolfgang; Hörst, Fabian; Kleesiek, Jens; Hellwig, Birte; Rahnenführer, Jörg; Rajcsanyi, Luisa; Peters, Triinu; Hinney, Anke; Placke, Jan-Malte; Sucker, Antje; Paschen, Annette; Becker, Jürgen C; Livingstone, Elisabeth; Zimmer, Lisa; Tasdogan, Alpaslan; Roesch, Alexander; Hadaschik, Eva; Schadendorf, Dirk; Griewank, Klaus; Ugurel, Selma.
Afiliación
  • Lodde GC; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: georg.lodde@uk-essen.de.
  • Zhao F; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: fang.zhao@uk-essen.de.
  • Herbst R; Department of Dermatology, Helios Klinikum Erfurt, Erfurt, Germany. Electronic address: rudolf.herbst@helios-gesundheit.de.
  • Terheyden P; Department of Dermatology, UKSH Campus Lübeck, Lübeck, Germany. Electronic address: patrick.terheyden@uksh.de.
  • Utikal J; Department of Dermatology, Venerology, and Allergology, University Medical Center, Ruprecht-Karls University of Heidelberg, 68167 Mannheim, Germany. Electronic address: jochen.utikal@umm.de.
  • Pföhler C; Department of Dermatology, Saarland University Medical School, Homburg, Saar, Germany. Electronic address: claudia.pfoehler@uks.eu.
  • Ulrich J; Department of Dermatology and Venereology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany. Electronic address: jens.ulrich@harzklinikum.com.
  • Kreuter A; Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Klinik Oberhausen, University Witten/Herdecke, Oberhausen, Germany. Electronic address: alexander.kreuter@helios-gesundheit.de.
  • Mohr P; Dermatological Center Buxtehude, Elbe Kliniken Buxtehude, Buxtehude, Germany. Electronic address: peter.mohr@elbekliniken.de.
  • Gutzmer R; Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany. Electronic address: ralf.gutzmer@muehlenkreiskliniken.de.
  • Meier F; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases, Dresden, Germany. Electronic address: friedegund.meier@unikli
  • Dippel E; Department of Dermatology Ludwigshafen, Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany. Electronic address: DIPPELE@klilu.de.
  • Weichenthal M; Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany. Electronic address: MWeichenthal@dermatology.uni-kiel.de.
  • Jansen P; Department of Dermatology, University Hospital Bonn, Bonn, Germany. Electronic address: philipp.jansen@ukbonn.de.
  • Kowall B; Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany. Electronic address: Bernd.Kowall@uk-essen.de.
  • Galetzka W; Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany. Electronic address: wolfgang.galetzka@uk-essen.de.
  • Hörst F; Institute for Artificial Intelligence in Medicine (IKIM), University Hospital Essen (AöR), Essen, Germany. Electronic address: fabian.hoerst@uk-essen.de.
  • Kleesiek J; Institute for Artificial Intelligence in Medicine (IKIM), University Hospital Essen (AöR), Essen, Germany. Electronic address: jens.kleesiek@uk-essen.de.
  • Hellwig B; Department of Statistics, TU Dortmund University, Dortmund, Germany. Electronic address: hellwig@statistik.tu-dortmund.de.
  • Rahnenführer J; Department of Statistics, TU Dortmund University, Dortmund, Germany. Electronic address: rahnenfuehrer@statistik.tu-dortmund.de.
  • Rajcsanyi L; Section for Molecular Genetics of Mental Disorders, University Hospital Essen, Essen Essen, Germany Center for Translational Neuro, and Behavioral Sciences, University Hospital Essen, Essen, Germany. Electronic address: luisa.rajcsanyi@uk-essen.de.
  • Peters T; Section for Molecular Genetics of Mental Disorders, University Hospital Essen, Essen Essen, Germany Center for Translational Neuro, and Behavioral Sciences, University Hospital Essen, Essen, Germany. Electronic address: triinu.peters@uni-due.de.
  • Hinney A; Section for Molecular Genetics of Mental Disorders, University Hospital Essen, Essen Essen, Germany Center for Translational Neuro, and Behavioral Sciences, University Hospital Essen, Essen, Germany. Electronic address: anke.hinney@uk-essen.de.
  • Placke JM; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany. Electronic address: jan-malte.placke@uk-essen.de.
  • Sucker A; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: antje.sucker@uk-essen.de.
  • Paschen A; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany. Electronic address: annette.paschen@uk-essen.de.
  • Becker JC; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany; Translational Skin Cancer Research, German Consortium for Translational Cancer Research (DKTK), Essen, Germany. E
  • Livingstone E; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: elisabeth.livingstone@uk-essen.de.
  • Zimmer L; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany. Electronic address: lisa.zimmer@uk-essen.de.
  • Tasdogan A; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany. Electronic address: alpaslan.tasdogan@uk-essen.de.
  • Roesch A; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany. Electronic address: alexander.rosch@uk-essen.de.
  • Hadaschik E; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: eva.hadaschik@uk-essen.de.
  • Schadendorf D; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany. Electronic address: dirk.schadendorf@uk-essen.de.
  • Griewank K; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany. Electronic address: klaus.griewank@uk-essen.de.
  • Ugurel S; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Essen, Düsseldorf, Germany. Electronic address: selma.ugurel@uk-essen.de.
Eur J Cancer ; 210: 114295, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39213786
ABSTRACT

BACKGROUND:

Immune checkpoint inhibition (ICI) currently is the most effective treatment to induce durable responses in metastatic melanoma. The aims of this study are the characterization of patients with early, late and non-response to ICI and analysis of survival outcomes in a real-world patient cohort.

METHODS:

Patients who received PD-1-based immunotherapy for non-resectable stage-IV melanoma in any therapy line were selected from the prospective multicenter real-world DeCOG study ADOREG-TRIM (NCT05750511). Patients showing complete (CR) or partial (PR) response already during the first 3 months of treatment (Early Responders, EarlyR) were compared to patients showing CR/PR at a later time (Late Responders, LateR), a stable disease (SD) and to patients showing progressive disease (Non-Responders, NonR).

RESULTS:

Of 522 patients, 8.2 % were EarlyR (n = 43), 19.0 % were LateR (n = 99), 37.0 % had a SD (n = 193) and 35.8 % were NonR (n = 187). EarlyR, LateR and SD patients had comparable baseline characteristics. Multivariate logbinomial regression analyses adjusted for age and sex revealed positive tumor PD-L1 (RR=1.99, 95 %-CI=1.14-3.46, p = 0.015), and normal serum CRP (RR=1.59, 95 %-CI=0.93-2.70, p = 0.036) as independently associated with the achievement of an early response compared to NonR. The median progression-free and overall survival was 46.0 months (95 % CI 19.1; NR) and 47.8 months (95 %-CI 36.9; NR) for EarlyR, NR (95 %-CI NR; NR) for LateR, 8.1 months (7.0; 10.4) and 35.4 months (29.2; NR) for SD, and 2.0 months (95 %-CI 1.9; 2.1) and 6.1 months (95 %-CI 4.6; 8.8) for NonR patients.

CONCLUSION:

Less than 10 % of metastatic melanoma patients achieved an early response during the first 3 months of PD-1-based immunotherapy. Early responders were not superior to late responders in terms of response durability and survival.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor de Muerte Celular Programada 1 / Inhibidores de Puntos de Control Inmunológico / Melanoma Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor de Muerte Celular Programada 1 / Inhibidores de Puntos de Control Inmunológico / Melanoma Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido